The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Approval of an immunotherapy for adjuvant NSCLC indication gives us new reasons for finding early-stage disease

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

FDA’s recent approval of an immunotherapy in the adjuvant setting for stage II-IIIA non-small cell lung cancer makes it all the more urgent to detect lung cancer at early stages.

The IMpower010 study compared adjuvant atezolizumab to standard of care in patients with complete resected stage IB-IIIA. For patients with stage IIA-IIIB the study demonstrated significant improved disease-free survival (DFS) in patients within PD-L1 ≥1% (HR=0.66;0.50-0.88) and for all randomized patients (HR=0.79; 0.64-0.96). 

Most impressive was the difference in patients with high PD-L1 expression (≥ 50%) (HR=0.43; 0.27-0.68), while no difference was seen in patients with tumors having PD-L1<1%, HR=0.97 (0.72-1.31). The adjuvant immunotherapy was given after 1-4 series of adjuvant chemotherapy for complete resected early-stage NSCLC. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Fred R. Hirsch, MD, PhD
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute
Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Byline
Fred R. Hirsch, MD, PhD
Executive director, Center for Thoracic Oncology, Mount Sinai Cancer, Mount Sinai Health System; Professor of medicine and pathology, Icahn School of Medicine; Joe Lowe and Louis Price Professor of Medicine, Associate director, Tisch Cancer Institute
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account